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Tendons are dense connective tissues arranged in a hierarchical
manner. Mature tendons are normally characterized by low cellular
density and this is one of themost obvious featureswhen looking at ten-
don histological preparations. About 90–95% of the cellular content of
tendon comprises tendon-speciﬁc cell types described in the literature
as tenoblasts and tenocytes, the latter being the terminally differentiat-
ed form (Kannus, 1997; Chuen et al., 2004). During development new-
born tendons have a very high cell-to-matrix ratio with tenoblasts of
various shapes and sizes aligned in long parallel chains. Following ten-
donmaturation, the ratio between cells andmatrix gradually decreases,
with tenoblasts transforming from an ovoid to a spindle and elongated
shape, speciﬁc for their differentiated counterparts, tenocytes (Ippolito
et al., 1980).
Although the general knowledge about the differentiated cells resid-
ing in tendon tissue has been developing in the latest years, still little is
known about their precursors. Stem/progenitor cells of mesenchymal
origin, such as the tendon lineage, are of great interest in order to under-
stand tendon development and healing processes. In 2007, Bi et al.
(2007)demonstrated that human andmouse tendons harbour a unique
cell population which has universal stem cell characteristics such as
clonogenicity, self-renewal capacity and multipotency. Compared to
bone marrow stromal stem cells, these tendon-derived cells expressed
high levels of Scleraxis (SCX), cartilage oligomeric matrix protein
(COMP), tenascin-C and tenomodulin (TNMD), all tendon-related fac-
tors, thus identifying their origin. Additionally, these isolated cells
showed the ability to regenerate tendon-like tissue after extended ex-
pansion in vitro and transplantation in vivo. However, the fact that the
cells of this population showed heterogeneity in their stem properties
and the possibility of containing tendon progenitor cells as well, made
the authors name them- tendon stem/progenitor cells (TSPCs).
The repair of musculoskeletal tissues often recapitulates the cellular
and molecular events of development. Thus, understanding the process
of tendon development can signiﬁcantly help to develop novel repair
strategies. So far, the knowledge on the ontogeny of the tendon lags
far behind other mesodermal tissues due to both the lack of speciﬁc
markers exclusive to the tendon lineage. However, the identiﬁcation
of the basic helix-loop-helix (bHLH) transcription factor Scx as a speciﬁc
and earlymarker of tendon progenitors during embryonic development
(Cserjesi et al., 1995; Schweitzer et al., 2001) and the study of mice
harbouring genetic mutations leading to tendon phenotypes, reviewed
in Tozer and Duprez (2005) and Liu et al. (2011), have provided some
insights into the onset of the tendon lineage and themolecules involved
in this process. Using knockout mouse models, further transcription
factors were identiﬁed to be essential for tendon differentiation and de-
velopment such asMohawk (Mkx), Egr1 and Egr2 (Ito et al., 2010; Lejard
et al., 2011; Guerquin et al., 2013).Tenomodulin was discovered in 2001 by Brandau et al. (2001) and
Shukunami et al. (2001) as a gene sharing high homology with
chondromodulin-1 (CHM1, alternative names chondromodulin-1 and
alternative abbreviations, CHM-I, LECT1, BRICD3 and MYETS1) (Hiraki
et al., 1991). Both research groups described high expression in tendons,
explaining the rationale behind its name. It was hinted to be useful as a
tendon-speciﬁc marker, which later on became an established marker
for the mature tendon and ligamentous lineage.
Despite great progress in deciphering tendon development, the
exact molecular pathways orchestrating tendon progenitor speciﬁca-
tion and differentiation still remain largely unknown. Therefore, further
studies are required to identify novel tendon-speciﬁcmarkers, to under-
stand their roles and to elucidate themolecular cascades occurring dur-
ing tendon development and maintenance.
In view of the above, the focus in this review is on TNMD, one of the
best so far tendon-speciﬁc marker genes. We carried out a systematic
review analysis on all available articles in the PubMed databank. The ex-
amination was performed by searching tenomodulin under its full
name, but also by its alternative names and abbreviations (tendin and
myodulin, TNMD and TeM). A summary of the selection of articles for
this review is shown in Fig. 1.
2. Tenomodulin
2.1. Gene discovery and nomenclature
TNMD was found independently by Brandau et al. (2001) and
Shukunami et al. (2001). Brandau's team named it tendin with the
justiﬁcation that it is highly expressed in tendons and ligaments.
Shukunami's team, on the other hand named it tenomodulin, since it
shares high homology to chondromodulin-I, but is expressed in ten-
dons, hence postulating a similar modulatory function in these tissues.
Tenomodulin also circulated around the literature very brieﬂy under
the name of myodulin (Pisani et al., 2004; Pisani et al., 2005). The au-
thors gave the alternative name myodulin based on detecting Tnmd
mRNA in Northern blot analysis of rat gastrocnemius muscles. As previ-
ously mentioned, its abbreviations in the literature are found under
TNMD and TeM.
2.2. Gene and protein structure
TNMD, Tnmd belongs to the new family of type II transmembrane
glycoproteins with a highly conserved cleavable C-terminal cysteine-
rich domain (Brandau et al., 2001; Shukunami et al., 2001). The TNMD,
Tnmd gene consists of seven exons localized on the X chromosome
(Fig. 2) and accounts for an approximately 1.4 kb transcript and a pre-
dicted protein consisting of 317 amino acids (Brandau et al., 2001;
Shukunami et al., 2001). Analysis of primary amino acid sequences
Fig. 1. Flow chart of the search strategy and study selection used in this systematic review.
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(Fig. 3).
The gene is composed of seven exons among which the second
encodes for the transmembrane domain and the last for the C-
terminal cysteine-rich domain that is conserved across species
(Fig. 3A). Unlike the Chm1 precursor, the Tnmd protein does not in-
clude a furin cleavage site, although a putative protease recognition
sequence (Arg-Xxx-Xxx-Arg) was identiﬁed at the position 233–
236 (Barr, 1991; Shukunami et al., 2005). The extracellular part,
prior the cleavage site, contains a BRICHOS extracellular domain
(Fig. 3B). This domain consists of a homologous sequence of approxi-
mately 100 amino acids containing a pair of conserved cysteine residues
(Sanchez-Pulido et al., 2002). BRICHOS has been found in several un-
related to Tnmd genes involved in dementia, respiratory distress and
cancer. It has been suggested that it participates in post-translational
processing, however the function remains unclear (Sanchez-Pulido
et al., 2002). In contrast to Chm1, which has two N-glycosylation sties
and one O-glycosylation site (Neame et al., 1990), Tnmd is absent of
these three sites, while it contains two N-glycosylation sites at position
94 and 180 (Brandau et al., 2001). Protein analyses in eye and periodon-
tal ligament revealed full length Tnmd protein as a double band of 40
and 45 kDa (Shukunami et al., 2005; Komiyama et al., 2013). It has
been experimentally proven that the 45 kDa band corresponds to the
glycosylated Tnmd, while the 40 kDa band refers to the non-
glycosylated Tnmd (Komiyama et al., 2013).Fig. 2. Schematic representation of the human TNMD gene.White boxes represent 5’′ and 3’′UT
TAA, stop codon.Tnmd contains a highly conserved C-terminal cysteine-rich do-
main (Shukunami et al., 2001), making up the part of the protein
sharing the highest resemblance to Chm1 (77% similarity/66% iden-
tity) (Brandau et al., 2001). This domain contains C-terminal hydro-
phobic tail with eight Cys residues forming four disulphide-bridges,
which are well conserved across vertebrate species (Shukunami
et al., 2005; Shukunami et al., 2006; Kondo et al., 2011) as shown
in Fig. 3. A smaller cyclic structure forming by single Cys280–Cys292 di-
sulphide bridge in Tnmd has been shown to exert an anti-angiogenic
function, while the other three disulphide-bridges are speculated to
hold this cyclic structure and the C-terminal hydrophobic tail separated
from each other to avoid the formation of intramolecular aggregates
(Miura et al., 2012). In certain tendon tissues, such as Achilles tendon
and chordae tendineae cordis (CTCs), 16 kDa cleaved C-terminal part
of Tnmd was detected in the collagenous extracellular matrix, which
suggested tissue-speciﬁc Tnmd secretion (Docheva et al., 2005;
Kimura et al., 2008).
Since TNMD and its homologue CHM1 are a novel class of proteins it
is very relevant to clarify the existence of isoforms as well as their exact
protein structure and function. A studydealingwith human tendon cells
and tissues, and using the I-TASSER molecular modelling programme,
has suggested that the TNMD gene has 3 possible isoforms I, II and III
with molecular weights of 37.1, 20.3 and 25.4 kDa, respectively (Qi
et al., 2012). However, further validation by carrying out Northern
blot analyses as well as speciﬁc PCR designed to clearly discriminateR sites, while orange boxes represent exons. Abbreviations: ATG, start codon; kb, kilo base;
Fig. 3.A comparison of the deduced amino acid sequences of tenomodulin proteins and structural features of thehumanTNMD. (A) Predicted amino acid sequences of human (Shukunami
et al., 2001, and Yamana et al. 2001),mouse (Brandau et al., 2001; Shukunami et al., 2001, and Yamana et al. 2001), and chick (Shukunami et al., 2006) tenomodulin. The conserved amino
acid residues are shaded and gaps were introduced for optimal alignment. Conserved cysteine residues are indicated in bold with an asterisk. The chicken sequence shares 62% homology
with themouse and human orthologs. The conserved amino.GenBank accession numbers for the aligned sequences are as follows: human TNMD, AF234259.1;mouse Tnmd, AF219993.1;
chick TNMD, AY156693. (B)HumanTNMDprotein includes a type II transmembrane domain at theN terminus, a BRICHOS domain (Sanchez-Pulido et al., 2002) and a C-terminal cysteine-
rich domain. The TNMDprotein contains two N-glycosylation sites within the BRICHOS domain. Abbreviations: C, cysteine; cTnmd; chicken tenomodulin; hTNMD, human tenomodulin; I,
isoleucine; K, lysine;mTnmd, mouse tenomodulin; N, asparagine; T, threonine; V, valine; TNMD, Tnmd, tenomodulin.
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mouse, Brandau et al. (2001) (Northern blot analyses on multiple
mouse tissues with Tnmd cDNA probe for exons 4–7) and Shukunami
et al. (2001) (Northern blot with 8 different mouse tissues and cDNA
probe encoding two thirds of the entire coding region) did not detect
Tnmd isoforms. Similar ﬁndings were observed in Northern blot investi-
gations on samples from wild type and knockout mice with full cDNA
probe and western blotting analyses of mouse tissues and anti-Tnmd
antibodies (Docheva et al., 2005; Shukunami et al., 2006; Takimoto
et al., 2012; Komiyama et al., 2013). This data suggests that TNMD iso-
forms might be species-speciﬁc. Interestingly, the programme-based
study predicted for each isoform a very different protein function: iso-
form I to be a cytosine methyltransferase; isoform II a SUMO-1-like
SENP-1 protease; and isoform III to be an α-syntrophin, pleckstrin ho-
mology domain scaffolding protein. A possible explanation behind the
suggestion that each isoform functions entirely different could be that
the novel and unstudied protein domain structures of TNMD and
CHM1 causes the available prediction platforms to search for minimal
homology scores, hence identifying totally different proteins. Despite
of the many open questions left, the study of Qi et al. (2012) strongly
urges for further analyses on the TNMD isoforms and exact protein do-
main structure and function.
2.3. Expression pattern
TNMD is a protein predominantly expressed in tendons and liga-
ments. The ﬁrst Northern blot analysis on new-born mouse tissueshowed the highest expression of Tnmd in skeletal muscle (Shukunami
et al., 2001), diaphragm and eye, even though an overall weak signal
was visible in almost all other screened tissues (Brandau et al., 2001). Fol-
lowing in situ hybridization and western blotting studies revealed that
the signal frommuscle tissue is mainly due to expression of Tnmd in ten-
dons and ligaments as well as in the muscle sheet epimysium (Brandau
et al., 2001; Docheva et al., 2005; Kimura et al., 2008; Komiyama et al.,
2013; Sato et al., 2014). In a temporal expression analysis in mice the
presence of the Tnmd transcript was weekly detected already at embry-
onic day E9.5 in developing limb buds (Brandau et al., 2001); however
a recent paper has ﬁrmly reported very strong TnmdmRNA expression
at day E14.5 corresponding to the differentiation stage of tendon progen-
itors (Havis et al., 2014). Furthermore, also tendon-like structures in the
heart, namely chordae tendineae cordis, demonstrated Tnmdmessenger
and protein existence in these areas (Kimura et al., 2008). Interestingly,
several papers have found Tnmd expression in themaxilla-facial region.
Komiyama et al. (2013) reported high Tnmd expression, by immuno-
histochemical analysis, in periodontal ligaments at 3 and 4 postnatal
weeks, marking the molar eruptive and post-eruptive phases when oc-
clusal forces are transferred to the teeth and the surrounding tissues.
Watahiki et al. (2008) discovered a speciﬁc expression of Tnmd in man-
dibular condylar cartilage at 1 week in rats. The masseter muscle is
compartmentalized by a laminar structure, which was shown to ex-
press by in situ hybridization Tnmd in mouse embryos at E12.5 to
E17.5 (Sato et al., 2014). Furthermore, Oshima et al. (2003) revealed
Tnmd expression at E15.5 in skin and eye using Northern blotting. The
exact localization of Tnmd mRNA in the eye was shown by in situ
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ganglion cell layer, lens ﬁbre cells, inner nuclear layer cells and pigment
epithelium of the retina (Oshima et al., 2003). TNMD expression was
also found by PCR in human subcutaneous adipose tissue and adipo-
cytes (Saiki et al., 2009). Last, in situ hybridization showed Tnmd ex-
pression in various parts of the adult mouse brain such as the dentate
gyrus, CA regions of the hippocampus, neurons in the cerebral nuclei,
cerebellum, Purkinje cells and neuronal cells in the cerebellar nucleus
(Brandau et al., 2001). However, a general notion should be taken that
Tnmd expression outside dense connective tissues, such as tendons
and ligaments, is very low. The main expression sites of TNMD, Tnmd
are summarized in Table. 1.Table 1
Expression pattern of TNMD, Tnmd.
Species Experimental source Methods Exp
Human Musculoskeletal tissues Real-time PCR Ten
CTC from patients IHC Ela
Adipose tissue DNA-MA, Real-time PCR Lea
spe
par
ora
sub
Cultured cells ICC Bon
PCR TSP
Porcine Pig heart and eyes RT-PCR, WB Cho
Rabbit 1-Week-old Japanese white rabbits ISH Ach
12-week-old Japanese white rabbits PCR CTC
Rat
Rotator cuff healing model in
19–21-week-old rats
Real-time PCR
ISH
Hea
upr
and
Mid
Achilles tendon healing model with
9–10-week-old rats
RT-PCR Upr
com
mu
inje
Mouse Embryos NB Wh
Hig
we
thy
car
IHC Sec
ISH Ten
epi
Ten
CD3
in l
ma
dia
PCR Hea
New-born IHC Pat
Ach
RT-PCR Hea
2- and 3-week-old mice IHC Per
4-Week-old mice NB/WB Wh
PCR Wh
ISH Cor
Ten
WB Ske
IHC Ach
NB Hig
Cultured cells PCR/IHC TSP
Chick Embryos (from HH stage 23–41) ISH Ten
Ten
per
Hin
NB Wh
ske
Cultured cells NB Ten
Abbreviations: CTC, chordae tendineae cordis; DNA, deoxyribonucleic acid; E, embryonic day; H
situ hybridization; MA, microarray; MSC, mesenchymal stem cell; NB, Northern blot; PCR
stem/progenitor cell; WB, western blot.2.4. Putative signalling pathway
TNMD is an established marker for the mature tendon and ligament
lineage (Shukunami et al., 2006) due to its high expression in these tis-
sues, segregating uncommitted from committed cells of this lineage. In
order to decipher upstream and downstream effectors of Tnmd many
knockout mouse models with tendon phenotypes have helped in un-
derstanding which factors or pathways affect Tnmd. Similarly, the loss
of Tnmd allows suggestions on which molecules might be downstream
effectors. It is important to emphasise that the most of the following
studies show correlations between Tnmd expression or function to
other genes and not a direct link in a common signalling cascade. Inression domains References
don, fat, muscle in Jelinsky et al. (2010)
stin-rich mid layer of CTC Kimura et al. (2008)
n and obese adipose subcutaneous tissue, more
ciﬁcally mammary glands, omental fat, tongue superior
t and main corpus, but also urethra, coronary artery,
l mucosa, ovary, skeletal muscle, bone marrow, colon,
stantia nigra and pituitary gland
Saiki et al. (2009)
e marrow-derived MSCs expressing Scx Alberton et al. (2012)
Cs Bi et al. (2007)
rdae and eye Kimura et al. (2008)
illes tendon Yukata et al. (2010)
interstitial cells Kimura et al. (2008)
ling tissues at 2-, 4-, 6-, 8-, 12-weeks, but signiﬁcantly
egulated in animals treated with FGF-2 at weeks 4, 6, 8
12 compared to normally healing tendons
substance of tendon at 2- and 8-weeks
Tokunaga et al. (2015)
egulation in the normally loaded Achilles tendon
pared to the animal where normal loading of the
scle-tendon unit was prevented by intramuscular Botox
ction
Eliasson et al. (2009)
ole embryos at E15.5 and E17.5 Oshima et al. (2003)
h expression in skeletal muscle, diaphragm and eye,
ak signals in brain, lung, liver, heart, kidney, skin,
mus and perichondrium- and periosteum-free rib
tilage
Brandau et al. (2001)
ondary lens ﬁbres and retina at E16.5 Oshima et al. (2003)
don of extrinsic ocular muscle, sclera, equatorial lens,
thelial cells at E16.5
dons at E14.5, E15.5, and E16.5
Oshima et al. (2003)
1- negative regions of tendons at E16.5. Strong signals
imb tendons and cruciate ligaments, tendons of the
sculus ﬂexor digitorum, ligament intercostal,
phragm, cortex, medulla of the thymus at E17.5
Shukunami et al. (2008)
rt from E14.5 to E18.5 Kimura et al. (2008)
ellar ligament, anterior and posterior cruciate ligament,
illes tendon of Sox9Cre/+;R26R
Sugimoto et al. (2013)
rt Kimura et al. (2008)
idontal ligaments Komiyama et al. (2013)
ole eye, skin Oshima et al. (2003)
ole eye, cornea, retina, sclera with ocular muscles
nea, sclera, retina
don, epimysium of skeletal muscle Shukunami et al. (2001)
letal muscle Oshima et al. (2004)
illes tendon Docheva et al. (2005)
h in tendon, low in eye and muscle
C Bi et al. (2007);
Alberton et al. (2015)
don primordia and tendons Shukunami et al. (2006)
don primordia and tendons, ligaments and
ichondrium
Shukunami et al. (2008)
d limb tendons at HH stage 30 Takimoto et al. (2012)
ole embryos from HH stage 25 to stage 35, tendon,
letal muscle, heart, skin and eye at HH stage 45
ocytes isolated from leg tendons at HH stage 41 Takimoto et al. (2012)
C, immunohistochemistry; HH, Hamburger Hamilton; ICC, immunocytochemistry; ISH, in
, polymerase chain reaction; RT, reverse transcriptase; Scx, Scleraxis; TSPC, tendon
6 S. Dex et al. / Gene 587 (2016) 1–17Fig. 4, we have summarized the so far reported, mostly indirect, links
between Tnmd and putative upstream and downstream factors.
Brent et al. (2005) reported that in Sox5 and Sox6 double knockout
mice, where skeletal elements failed to undergo normal chondrogenic
differentiation, the domain of Scx is broadened and accompanied by
the expression of Tnmd. These observations proposed that Tnmdmight
be a direct target of Scx transcriptional activities. Towards the same sug-
gestion led also an in vitro experiment where over-expression of Scx
triggered the up-regulation of Tnmd in cultured chicken tenocytes
(Shukunami et al., 2006). Additional evidence came from the study of
Murchison et al. (2007)which reported the phenotype of the Scx knock-
out mice. These mice are characterized by severe tendon defects, rang-
ing from a dramatic failure in progenitor differentiation to the
formation of small and poorly organized force transmitting tendons. In-
terestingly, in these mice the screening of the expression of several
genes known to be expressed in tendons revealed the complete loss of
expression of Tnmd and type XIV collagen at E16.5 (Murchison et al.,
2007). Another study in 2012 validated that by overexpression of Scx
inmesenchymal stem cells Tnmd expression is signiﬁcantly upregulated
in a cell type which normally does not express Scx nor Tnmd (Alberton
et al., 2012).
Another factor participating in Tnmd signalling is the growth
differentiation factormyostatin. The deletion ofmyostatin inmice result-
ed in small, brittle and hypocellular tendons (Mendias et al., 2008),
a phenotype similar, in term of cell density, to the one found in the
Tnmd-deﬁcient mice (Docheva et al., 2005). Moreover, these mice
showed a decrease in Scx and Tnmd expression (Mendias et al., 2008)
and myostatin stimulation of ﬁbroblasts led to Scx and Tnmd mRNAFig. 4. Summary of putative upstreamand downstream factors in Tnmd-related signalling.
The ﬁgure is based on studies showing mostly correlations, indicated by the question
marks, between TNMD expression or function to other genes and not a direct link in a
common signalling cascade. Based on Alberton et al. (2012); Alberton et al. (2015);
Brent et al. (2005); Docheva et al. (2005); Frolova et al. (2014); Kimura et al. (2008);
Kyriakides et al. (1998); Lejard et al. (2011); Liu et al. (2010); Mendias et al. (2008);
Miyabara et al. (2014); Murchison et al. (2007); and Shukunami et al. (2006).
Abbreviations: Egr, early growth response protein; MMP, matrix metalloproteinase;
Thbs, thrombospondin; VEGF, vascular endothelial growth factor.upregulation, suggesting myostatin as an upstream factor in the Tnmd
pathway by ﬁrst inducing Scx expression.
The expression of an Egr-like transcription factor (Frommer et al.,
1996) in tendon precursor cells of Drosophilamotivated the generation
of Egr1 and Egr2 mutant mice and chicks in 2011 for investigation of
their involvement in vertebrate tendon development (Lejard et al.,
2011). This study concluded that Egr1 and Egr2 expression in tendon
cells was associated with the upregulation of Col1a1 from E11.5
onwards by trans-activating its proximal promoter as well as other col-
lagens in tendon cell differentiation in embryonic limbs. Furthermore,
the authors established that Egr genes were activated by muscle-
derived FGF4 and are able to induce de novo expression of Scx. Moreover,
both Egr1 and Egr2 knockouts were characterized by reduced Col1a1
transcripts together with decreased number of collagen ﬁbrils (Lejard
et al., 2011). It would be interesting to investigate if loss of Egr1/2 also
affects Tnmd expression.
The absence of theMohwak (Mkx) homebox gene inmouse led to an
abnormal tendon phenotype including an effect on Tnmd expression
(Liu et al., 2010). These mice exhibited tendons with inferior size com-
pared to normal mice. On a molecular level,Mkxmutants revealed sig-
niﬁcantly lower Tnmd levels as well as collagen I and ﬁbromodulin (Liu
et al., 2010). Tnmd mRNA was downregulated in Scx and Mkx mutant
mice around E16.5 (Murchison et al., 2007; Liu et al., 2010). Interesting-
ly, Scxmutantmice show tendon defects as early as E13.5, while the ten-
don phenotype ofMkxmutants is ﬁrst visible at E16.5 despite that Scx
expression is sustained in these animals (Murchison et al., 2007; Liu
et al., 2010). This clearly suggests that in tendon development Scx acts
prior toMkx, but with regards to regulation of Tnmd both Scx and Mkx
can perform independently from each other as upstream factors.
The use of gene silencing experiments was valuable for understand-
ing why bone marrow-derived stem cells (BMDSCs) from horse, which
in culture have very low amounts of TNMD compared to tendons,
showed similar TNMD expression when cultured in collagen gels con-
taining a glycogen synthase kinase-3 (GSK-3) inhibitor (Miyabara
et al., 2014). Application of inhibitor or small interference RNA corre-
sponding to GSK-3α/β into BMDSCs resulted in nuclear translocation
of β-catenin and this drove the expression of TNMD. Since the levels of
Scx and Mkx were unaffected in the above conditions, it points out
that the Wnt/β-catenin signalling works independent from these tran-
scription factors (Miyabara et al., 2014).
Next, a Tnmd knockout mouse model study revealed that loss of
Tnmd results in reduced proliferation and earlier onset of senescence
in TSPCs (Alberton et al., 2015). The study compared tenogenic markers
in both genotypes ofwhich no differenceswere observed, except for the
absence of Tnmd transcript in mutant mice. However, analysis of TSPCs
self-renewal showed that Tnmd knockout TSPCs had signiﬁcantly lower
clonogenic ability as well as proliferated less after passage 3 and
reached an earlier plateau compared towildtype TSPCs. Thiswas further
accompaniedwith signiﬁcant downregulation of the proliferativemark-
er Cyclin D1 in Tnmd knockout TSPCs. Another striking feature of the
Tnmd knockout TSPCs is that at an earlier passage they show signs of se-
nescence, revealed byβ-galatosidase staining, and the number of senes-
cent cells was always larger in the knockouts. In addition a profound
upregulation of p53was detected in the knockout cells. Taken together,
these ﬁndings suggest that loss of Tnmd results in reduced proliferation
and premature ageing of the TSPCs (Alberton et al., 2015) and second-
ary to this there is a distorted gene expression balance (Cyclin D1 and
p53). This ﬁnding is in line with the analyses of the Tnmd knockout
mousemodel, which revealed reduced cellular density and proliferation
in vivo (Docheva et al., 2005). In addition, Tnmdmutants showed an ab-
normal collagen ﬁbril phenotype with pathologically thicker ﬁbrils, re-
sembling signs of premature tendon matrix ageing. In sum, it can be
suggested that collagen type I, proliferation and senescent-related fac-
tors are belonging to the putative downstream effectors. Still, at this
stage of the research it is not possible to clarify how exactly Tnmd is reg-
ulating the above factors. Since Tnmd shares high homologywith Chm1,
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factor. However, the study of Tnmd expression in Chm1 null mice and
vice versa of Chm1 expression in Tnmd-deﬁcient mice, showed no up-
regulation of neither of the genes, suggesting that the loss of these
genes is likely to be compensated by other factors (Brandau et al.,
2002; Docheva et al., 2005).
Interestingly, both Thrombospondin-2 (Thbs-2) and Thbs-4 knockout
mice both display tendon phenotypes consisting of abnormally large
collagen ﬁbrils (Kyriakides et al., 1998; Frolova et al., 2014), a similar
outcome to the collagen ﬁbril phenotype of Tnmd deﬁcient mice.
These observations are open invitations for exploring if Thbs mem-
bers and Tnmd are participating or connected in the same molecular
cascade.
Last, the study analysing ruptures of human CTCs revealed that in
the affected area TNMD expression is downregulated, but VEGF-A and
several MMP (MMP1, 2 and 13) expressions are upregulated. Further-
more, tube formation andmobilization of human coronary artery endo-
thelial cells were dramatically inhibited when treated with conditioned
media from CTC or NIH3T3 cells that were transfected with the Tnmd
C-terminal domain. On the contrary, when cultured with conditioned
media from CTC cells treated with Tnmd siRNA their capability forming
ability was recovered. Hence, these experimental ﬁndings conﬁrm an
antiangiogenic role of Tnmd in CTCs (Kimura et al., 2008).
We strongly stress that in future research it would be essential to de-
cipher what are the exact binding partners of Tnmd. This may help us to
explain, for example, opposing effects such as stimulating the prolifera-
tion of tendon-derived cells, but inhibiting vascular cells. At present, we
speculate that Tnmd might be a co-factor regulating the function of a
growth factor or growth factor receptor and hence, depending on the
availability, act as a stimulator or inhibitor.Fig. 5. Current model of the tenogenic cascade and TNMD involvement. TNMD is marked in oran
Berasi et al. 2011; Eloy-Trinquet et al. (2009); Havis et al. (2014); Huang et al. 2015; Lee et al. (
and Tempfer et al. (2009). Abbreviations: Aqp1, aquaporin 1; BMP, bone morphogenetic prot
protein; Eya, eyes absent transcription factor; FGF, ﬁbroblast growth factor; Htra3, HtrA serine
Scleraxis; SMA, smooth muscle actin; TGF, transforming growth factor; Thbs, thrombospondin2.5. Tenogenic differentiation cascade
The up-to-date paradigm underlining the putative tendon cell com-
mitment and differentiation process is still very controversial and not
fully understood; however the involvement of Tnmd in several steps
of this process became very apparent in recent studies. Fig. 5 represents
themolecular orchestra of tendon cell differentiation and importantly, it
marks the participation of Tnmd in speciﬁc commitment steps. In early
tendon development, embryonic mesenchymal progenitors at E10.5
commit into the tendon lineage by ﬁrst elevating the Scx transcription
factor in developing sclerotomes of the somites, mesenchymal cells in
the body wall and limb buds in mouse embryo (Brent et al., 2003). Fur-
thermore, follow up studies suggested that the initial Scx expression is
mediated by transcription factors Pea3 and Erm, which are activated
by FGF signalling (Brent and Tabin, 2004; Eloy-Trinquet et al., 2009).
Among the FGF family the critical members in mice are FGFs 4 and 6,
and in chick FGFs 4 and 8. Pryce et al. (2009) reported that in addition
to FGFs, TGFβ (Tgfβ) signalling is also critical in tendon progenitor
differentiation via direct induction of Scx expression. In this paper, the
tendon phenotypes of Tgfb2−/−;Tgfb3−/− double mutant, or the cor-
responding receptors, revealed that TGFβ signalling acts later than FGF
signalling since the tendon phenotype was ﬁrst manifested at E12.5,
while the tendon condensation and Scx-positive tendon cells were nor-
mal at E11.5.
Next, a breakthrough paper based on transcriptome analysis com-
paring expression proﬁles of a variety of genes in ScxGFP-positive ten-
don cells derived from different embryonic tendon development
stages, resulted in more clear picture of the molecular events during
tendon cell differentiation (Havis et al., 2014). By comparing cells
from E11.5, corresponding to tendon progenitors, to cells from E14.5,ge, transcription factors in blue and other genes in black. Based on Alberton et al. (2015);
2015); Liu et al. (2014); Mienaltowski et al. (2013); Pryce et al. (2009); Shen et al. (2013);
ein; Col, collagen; COMP, cartilage oligomeric matrix protein; Egr, early growth response
peptidase 3; IFM, interfascicular matrix; Mkx, Mohawk; Sca-1, stem cells antigen-1; Scx,
; Tnmd, tenomodulin.
Fig. 6. Research articles published annually including tenomodulin. (A) All articles
published on Pubmed covering tenomodulin and its alternative names tendin and
myodulin as well as its abbreviations TNMD and TeM. (B) Distribution of the published
research on tenomodulin into four main categories. This ﬁgure only includes research
published in English and full-text research articles.
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found a signiﬁcant upregulation of Tnmd, Col1a1, Col3a1, Col5a1,
Col6a1, Col12a1 and Col14a1 and two novel and unrelated so far to ten-
don genes, namely aquaporin 1 (Aqp1) and HtrA serine peptidase 3
(Htra3). With regards to the further maturation of tenoblasts towards
tenocytes the following studies suggested the essential contribution of
the Tnmd, Mkx, Erg 1/2, and Thbs-4 (Docheva et al., 2005; Liu et al.,
2010; Lejard et al., 2011; Alberton et al., 2012; Barsby et al., 2014;
Onizuka et al., 2014). The Scx expression in tenocytes remains at
present debatable. Scx signals are visible in the mature cells in ScxGFP
reporter mice (Sugimoto et al., 2013). However, from this transgenic
model is not clear how strong the levels of endogenous Scx in these
cells are.
With regards to tendon differentiation during tendon postnatal ho-
meostasis/maintenance or at times of tendon healing, the commitment
cascade is still very elusive. Cumulatively the few articles providing
some information on this topic are suggesting that the above process
might be mediated by the adult TSPCs or perivascular stem cells or ten-
don intra-fascicular matrix stem cells, or even a mixture of all these cell
types depending on the circumstances (Bi et al., 2007; Tempfer et al.,
2009; Rui et al., 2010; Mienaltowski et al., 2013; Liu et al., 2014;
Alberton et al., 2015; Docheva et al., 2015; Lee et al., 2015).
Mienaltowski et al. (2013) actually proposed that in tendons there is a
regional distribution of different stem/progenitor cells. Speciﬁcally,
they analysed two subpopulations; one originating from the peritenon
and the other from the tendon proper of mouse Achilles tendons.
Comparison between these subpopulations revealed that the cells
from the tendon proper are more proliferative and exhibit higher levels
of tendon-related markers, such as Tnmd and Scx, while peritenon-
derived cells showed increased vascular and pericyte markers. As illus-
trated in Fig. 5 these adult cell types share some marker gene expres-
sion; however their identity, density, exact location and distribution
are still not fully understood. Importantly, Tnmd expression has been
strongly connected with the adult TSPC cell type (Bi et al., 2007;
Alberton et al., 2015).
Taken together, even though our knowledge is being gradually
enriched about what genes are expressed in tendon precursor cells,
still very little is known whether they originate from embryonic-,
TSPC- or the perivascular cell lineages aswell as how exactly the various
molecular factor are interwoven in the progression of the tendon differ-
entiation programme. For these reasons it is highly important to identify
further markers exclusive to tendons and their residing stem, progeni-
tor and mature cells. Speciﬁcally for the Tnmd signalling pathway a de-
tailed analysis on the expression of other genes in loss-of-function
experimental models may clarify the compensatory mechanisms. Chro-
matin immunoprecipitation can rule out which transcription factors di-
rectly interact with the Tnmd promoter, while pool-down assays with
Tnmd antibody might help identifying possible directly binding mole-
cules. Last, since tendons are mechano-sensitive tissues, follow up
studies can aim at testing if and how Tnmd is regulated in vitro and
in vivo by mechanical stimuli.
2.6. Tenomodulin functional analyses
Ever since the discovery in 2001, TNMD gained gradual attention in
the tendon research ﬁeld with an immense rise of publications just in
the recent years as depicted in Fig. 6A. Altogether 146 articles and ab-
stracts on Pubmed have been published covering TNMD until the end
of 2015. After exclusion of articles only available in abstract form and
foreign language articles, we can group the remaining 128 full-text pub-
lications into four categories; namely into studies looking into functions
of TNMD, articles using TNMD as a tendon marker, research observing
correlations between TNMD mutations and a variety of diseases, and
lastly reviews Fig. 6B.
From this analysis it becomes obvious thatmost of the studies utilize
TNMD in research as a tendonmarker. In contrast, very little research, 16full-text studies, were conducted on determining the functional role of
TNMD in tendons and other tissues. A summary and detail comments
on the so far known TNMD functions are shown in Table 2, which is or-
ganized in chronological appearance of the articles from the discovery
of TNMD in 2001 to the end of 2015.
From this table we see major breakthroughs in the functions of
TNMD not just in tendons, but also in other tissues and cells. In tendons
it proves to have beneﬁcial functions for the maintenance of healthy
and functional tissue, because its loss results in distorted collagen
ﬁbrillogenesis, reduced cell density and overall premature tendon
ageing. Tnmd exerts a positive effect on TSPCs by sustaining their
stem cell like features such as promoting self-renewal and delaying
senescence, and the proliferative effect can be carried out exclusively
by the Tnmd C-terminal cysteine-rich domain (Alberton et al., 2015).
Another discovered function of Tnmd is the contribution to proper
adhesion of periodontal ﬁbroblasts, which have high gene expres-
sion (Komiyama et al., 2013).
Intriguingly, the proliferative inﬂuence of Tnmdwas shown to be de-
pendent on the cell type. For example, human retinal endothelial cells
transduced with Tnmd exhibited a reduction in proliferation. In addi-
tion, Tnmd lowered the angiogenic migration of human umbilical vein
endothelial cells (HUVECs) as reported by Oshima et al. (2003) and
Oshima et al. (2004). Transduction of Tnmd in human melanoma cells
resulted in suppression of tumour growth in ectopic in vivo model,
due to decreased vessel density most likely because of reduced endo-
thelial cell migration (Oshima et al., 2004). With respect to organismal
vessel formation in vivo it is clear that lack of Tnmd does not affect an-
giogenesis in tendon and retina development since the knockout
model revealed no major differences to wildtype mice (Docheva et al.,
2005). Still, the latter ﬁnding is open for discussion because a study
with recombinant Tnmd has shown an obliterating effect on retinal
Table 2
Summary of the discovered functions of TNMD, Tnmd.
Reference Experimental model Study type Findings and functions of Tnmd
Brandau et al. (2001) Northern blot analysis of new born mouse RNA; ISH
on E17.5 mouse embryos and adult mouse brain;
cloning of human and mouse Tnmd cDNA; genomic
analysis of human Tnmd organization
Genomic study and in vivo - Strong expression of 1.5 kb Tnmd transcript in diaphragm, skeletal
muscle and eye; low expression in brain, liver, lung, kidney, heart,
thymus and perichondrium- and periosteum-free ribcage; Tnmd
transcript found in tendons and ligaments but also in the brain,
spinal cord, liver, lungs, bowel, thymus and eye of E17.5 mouse
embryos; high expression of TnmdmRNA in the dentate gyrus, CA
regions of the hippocampus, neurones in the cerebral nuclei,
Purkinje cells and neuronal cells in the cerebellar nucleus, neurons
in the anterior and posterior horn of the spinal cord and neurons
from all cell layers in the cerebral cortex of adult mice.
- Mouse and human Tnmd share 89% homology, similarity
(54%) and identity (31%) to Chm1, especially with the
C-terminal (77% and 66%); 7 exons found.
Shukunami et al.
(2001)
Cloning of mouse Tnmd; Northern blot analysis of
mouse tissues; ISH of mouse skeletal muscle
Genomic study and in vivo - Cloning of Tnmd full-length reveals novel protein of 317 amino
acid residues; predicted amino acid sequence revealed 33%
overall identity with mouse Chm1 precursor; structural
features include singly transmembrane domain at the
N-terminal region and the putative angiogenic domain with
eight cysteine residues; Tnmd lacked a hormone-processing
signal compared to Chm1, suggesting it may function as a type
II transmembrane protein on cell surface.
- Tnmd transcript of 1.4 kb detected in skeletal muscle; Tnmd
expression not associated with muscle ﬁbres, but rather with
epimysium and tendon.
Oshima et al. (2003) Northern blot analysis on mouse embryos; ISH on
eyes of mouse embryos; human retinal endothelial
cells (HRECs) transduced with Tnmd; human
umbilical vein endothelial cells (HUVECs)
co-cultured with HRECs transduced with Tnmd
In vivo and in vitro -TnmdmRNA expression detectable from day E15.5 and present
in eye and skin; localization on Tnmd transcript on the
extraocular muscle, sclerocornea, lens ﬁbre cells, ganglion cell layer,
inner nuclear layer cells and pigment epithelium of the retina.
- Effective autocrine suppression of cell proliferation and
capillary-like morphogenesis of retina vascular endothelial
cells; conditioned media from soluble Tnmd-overexpressing
cells also showed marked inhibitory effect on angiogenesis.
Oshima et al. (2004) Adenoviral expression system to force expression
of Tnmd C-Terminal in HUVECs; C57BL/6 mouse
model subcutaneously injected with melanoma
tumour cells; histological analysis of melanoma
tumour cells injected into mice; transduction of
Tnmd into BL-6 melanoma cells
In vivo and in vitro - Transduction of Tnmd into HUVECS impaired tube formation
of HUVECs cultured in Matrigel; conditioned media from COS7
cells transfected with Tnmd impaired tube formation of
HUVECs; transformation of HUVECS with Tnmd downregulated
VEGF synthesis to 4–50% of normal levels; migration of HUVECs
in response to VEGF was signiﬁcantly affected after Tnmd
transduction.
- Formed tumours were 46% smaller compared to
Ad-EGFP-transduced melanoma cells; visible inhibition of
angiogenesis in implanted tumours and decreased microvessel
density; no effect on growth rate.
Pisani et al. (2004) Northern blot analysis on gastrocnemius muscle of
rats; RT-PCR analysis of tendons separated from
soleus muscle and tendon-free soleus muscle of
rats and Tnmd in primary human muscle cells
derived from single satellite cells; quantitative
Northern blot analysis of C2C12 mouse cell line;
overexpression of Tnmd fused to FLAG peptide and
immunoﬂuorescence to FLAG; western blot
analysis of myodulin-FLAG fusion protein;
co-culture experiment of C2C12 mouse myoblast
with H5V cells; proliferation of WTmuscle cells and
Tnmd-FLAG C2C12 cells compared; Tnmd
expression in hind limb suspension model in rats
In vivo and in vitro -Tnmd mRNA found in muscle ﬁbres and tendons; Tnmd
transcript found at the myoblast proliferating stage and
myotube differentiated stage; Tnmd transcript found in C2C12
cells without any signiﬁcant difference in expression levels
between proliferating and differentiated stages; evidence of a
muscle cell surface protein.
- Tnmd-FLAG fusion protein = 44 kDa, FLAG = 1 kDa so mass
of Tnmd = 43 kDa. Calculated mass = 37.047.
- Tnmd has an active role in invasive action of endothelial cells,
without evidence of extracellular Tnmd secretion; no
differences observed in proliferative capacity between WT
muscle cells and Tnmd-FLAG C2C12 cells, even with the
addition of FGF-2; soleus muscle mass decrease resulted in
capillary loss resulting in three-fold Tnmd downregulation and
2-fold upregulation the in opposite condition.
Docheva et al. (2005) Generation of the Tnmd KO mouse model;
Northern blot analysis of Tnmd in new-born
thymus, eye, tendon, muscle and heart tissues;
oxygen-induced retinopathy model (OIR); electron
microscopy of Achilles tendons;
immunohistochemical analysis of collagens,
decorin, lumican, aggrecan and matrilin-2
In vivo - Successful generation of Tnmd KOmouse line validated by lack
of Tnmd transcript; high Tnmd expression in tendons and at
lower levels in eye and muscle.
- Probing of tendon extracts with an antibody raised against the
C-terminal domain of Tnmd, detected a protein signal of 16 kDa
corresponding to the cleavable C-terminal cysteine-rich
extracellular domain; suggestion that C-terminal cysteine rich
domain of Tnmd is rapidly cleaved in vivo
- No changes in retinal vascularization seen in both genotypes
after OIR.
- Loss of Tnmd expression resulted in decreased tenocyte
proliferation and reduced tenocyte density in vivo.
- No changes in extracellular matrix protein production like
collagen type I, II, III and VI and decorin, lumican, aggrecan and
matrilin-2; collagen ﬁbrils showed signiﬁcantly increased
average diameters
(continued on next page)
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Table 2 (continued)
Reference Experimental model Study type Findings and functions of Tnmd
Pisani et al. (2005) Yeast transformation with mouse Tnmd vector
including C-terminal region and western blotting;
puriﬁcation of Tnmd in yeast by column
puriﬁcation; co-culturing C2C12 and H5V cells
together with modiﬁed yeast
In vitro - Mouse Tnmd could be expressed at the plasma membrane of
Saccharomyces cerevisiae in an N-glycosylated state.
- Murine Tnmd can be puriﬁed from yeast; detection of three
different bands of which one shows Tnmd in a glycosylated
state (65 kDa).
- Mouse Tnmd expressed in yeast fully functional by
increasing invasive potential of C2C12 cells in H5V co-culture
system.
Shukunami et al.
(2006)
ISH on developing chick embryos; retroviral
expression of Scx in chick tenocytes and
chondrocytes; misexpression of RCAS-cScx by
electroporation into hind limb
In vivo and in vitro - At stage 23, Scx expression in the syndetome has extended
to the tail region and Tnmd detectable in anterior eight
somites; at stage 25, Tnmd and Scx detectable in regions
adjacent to the myotome; at stage 32 and later, Scx and
Tnmd displayed similar expression proﬁles in developing
tendons.
- Upregulation of Tnmd in tenocytes but not chondrocytes;
no induction of generation of additional tendons but
resulted in upregulation of Tnmd in tendons at stage 33 and
later.
Watahiki et al., 2008 Quantitative PCR of mandibular condylar cartilage
and tibial growth plate cartilage of 1- and 5 week
old rats; IHC analysis on mandibular-, condylar-
and tibial cartilage of 1- and 5- week old rats
In vivo - Mandibular condylar cartilage showed higher mRNA levels
of Tnmd than tibial growth plate cartilage; mandibular
condylar cartilage 1-week-old rats presented higher Tnmd
mRNA levels than 5-weeks-old rats; Tnmd was found on
condylar cartilage except on ﬁbrous layer; Tnmd only
detected in the hypertrophic layer and part of articular
cartilage.
Shukunami et al.
(2008)
In situ hybridization on developing mouse at E14.5;
immunohistochemical analysis on developing
mouse forelimb; ISH on avascular mesenchyme and
vertebrae of developing chick
In vivo - mRNA localized in developing tendons which were
co-localized to Scx expression; Tnmd staining spotted in
cartilage and localization restricted to the PECAM-1 negative
region of the developing tendons; ﬁrst identiﬁed in
posterior regions of limb mesenchyme at HH stage 23 and
later expressed in attachment sites connecting cartilage and
muscle; at HH stage 30, distinct expression pattern adjacent
to MyoD-positive domain marking the myotome and
partially overlapping with Scx expression; Tnmd-positive
domains were lacking blood vessels; Tnmd expression ex-
clusive to connective tissues including intervertebral region,
perichondrium of vertebrae and ligaments; Tnmd only iden-
tiﬁed in peripheral region where thick bundles of collagen
ﬁbres were present.
Wang et al. (2012) OIR in mice; injection of commercially produced
recombinant Tnmd into eye for analysis of blood
vessel patterns
In vivo - In OIR model, fewer central non-perfused areas were
observed in Tnmd-injected eyes than in PBS-injected eyes;
signiﬁcantly less nuclei in new blood vessels breaking in
each retinal cross-section of Tnmd-treated- compared to
PBS-treated mice; suggestion of potential role of Tnmd in
prevention and treatment of ocular neovascularization.
Qi et al. (2012) I-TASSER protein three-dimensional conformation
modelling prediction; human and porcine
tenocytes; knock- down of human FCR cells; Tnmd
western blotting of pig, horse and human tendon
cells; ICC on Tnmd isoforms overexpressed in
COS-7 cells
Computer analysis and
in vitro
- Three TNMD transcripts with molecular weights of 37.1,
20.3 and 25.4 kDa for isoforms I, II and II respectively
proposed and veriﬁed by western blot from human cells;
isoforms I and II localized perinuclear and isoform III on
cytoplasm; predicted function of TNMD I = cytosine
methyltransferase, II = SUMO–1-like SENP-1 protease,
III = α-syntrophin, pleckstrin homology domain scaffolding
protein.
- Knockdown of all isoforms resulted in reduced cell
proliferation and downregulation of myostatin and Scleraxis.
Komiyama et al.
(2013)
Tnmd IHC on WT mouse molars; FL-, CTD-, CS-,
BRICHOS-, and EC Tnmd overexpression in NIH3T3
and hPDL cells; cleavage of N-glycans and
inhibition of glycosylation in vitro analysis by
adding tunicamycin and digesting cell lysates with
PNGaseF respectively; analysis of adhesion capacity
of Tnmd KO mouse ﬁbroblasts
In vivo and in vitro - Tnmd expression is related to time of tooth eruption at 2–3
weeks of age; Tnmd localized in Golgi apparatus, microtubules
and plasma membrane of PDL cells.
- 45-kDa Tnmd protein is likely to be glycosylated form;40-kDa
protein the non-glycosylated Tnmd protein.
- Tnmd overexpression resulted in enhanced adhesion of PDL
and NIH3T3 cells to collagen I and increased surface area;
Tnmd KO ﬁbroblasts showed decreased cell adhesion;
BRICHOS domain or CS region seem responsible for
Tnmd-mediated improvement of cell adhesion in Tnmd
overexpressing NIH3T3 cells.
Miyabara et al. (2014) Wnt in vitro model; equine BMSCs cultured in
collagen gel; nuclear translocation of ß-catenin in
glycogen synthase kinase-3 inhibitor-treated
BMSCs
In vitro - mRNA expression of Tnmd in equine BMSCs increased when
Wnt pathway was activated, comparable to levels in tendon.
- Concluded regulation of tenomodulin expression via
Wnt/ß-catenin signalling.
Sato et al. (2014) Tnmd messenger analysis using qPCR of masseter
muscle (MM) from C57/BL6 mice; ISH of Tnmd
transcript MM
In vivo - Level of Tnmd RNA increased from E12.5-E17.5 and
decreased after birth; CD31 and VEGF mRNA levels in the
MM remained constant from E12.5-E18.5 and low after
birth; Tnmd mRNA found in the middle region of the MM at
E12.5 as well as in the muscle-bone junction from E14.5
onwards.
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Reference Experimental model Study type Findings and functions of Tnmd
Alberton et al. (2015) Self-renewal comparison between WT and Tnmd
KO TSPC; transfection of full-length and C-terminal
domain of Tnmd in Tnmd KO mouse TSPCs;
multipotential comparison on TSPCs
In vitro - Tnmd KO TSPCs show reduced proliferative capacity.
- C-terminal alone restores proliferation in Tnmd KO TSPCs.
- Loss of Tnmd results in premature and increased senescence of
TSPCs compared to WT.
- Lack of Tnmd does not affect multipotential in TSPC.
Abbreviations: Ad-EGFP, adenovirus vector encoding enhanced green ﬂuorescent protein; BMSCs, bone marrow stromal cells; C2C12, mouse myoblast cell line;C57BL/6, C57 black 6;CA
region, Cornu Ammonis region; cDNA, complementary deoxyribonucleic acid; Chm1; chondromodulin-1; COS-7, African green monkey ﬁbroblast-like kidney cell line; CS, mutant with
deleted cleavage site; CTD, C-terminal domain deletion mutant; E, embryonic day; EC domain, mutant with entire extracellular portion of Tnmd deleted; FCR, ﬂexor carpi radialis; FGF-
2, ﬁbroblast growth factor-2; FL, full length Tnmd; H5V, mouse embryonic heart endothelial cells; HH, Hamburger-Hamilton stage; hPDL, human periodontal ligament; ICC, immunocy-
tochemistry; IHC, immunohistochemistry; ISH, in situ hybridization; I-TASSER, iterative, threading assembly reﬁnement; kb, kilo base; kDa, kilodalton; KO, knockout; mRNA, messenger
ribonucleic acid; NIH3T3, mouse embryonic ﬁbroblasts; OIR, oxygen-induced retinopathy; PBS, phosphate-buffered saline; PDL, periodontal ligament; PNGaseF, peptide-N-glycosidase F;
qPCR, quantitative PCR; RCAS-cScx, replication-competent avian sarcoma-leukosis virus-copy Scleraxis; RNA, ribonucleic acid; RT-PCR, reverse transcriptase-polymerase chain reaction;
Scx, Scleraxis; SUMO, small ubiquitin-like modiﬁer; Tnmd, tenomodulin; VEGF, vascular endothelial growth factor; WT, wildtype.
11S. Dex et al. / Gene 587 (2016) 1–17vessels when Tnmd was injected in the vitreous body in vivo (Wang
et al., 2012). In this study, however, information and validation of the
produced Tnmd were not included and at present the protein is not
available for purchase from the producer company. Last, the study on
CTCs demonstrated that in this tissue type Tnmd prevents vasculariza-
tion (Kimura et al., 2008).
Now that some Tnmd functions have been exposed it is also equally
important to decipher in follow up studies how exactly Tnmd exerts
these. As already discussed previously, the way to deliver the necessary
explanations is via narrowing down the exact signalling pathway of
Tnmd. This will not only allow a complete understanding of the role of
Tnmd in the domains where is expressed, but will also enable concrete
manipulation of its effect in possible clinical applications.
2.7. Tenomodulin as lineage marker
As observed in Fig. 6most of the full-text research papers containing
TNMD have used it as a gene marker for the tendon and ligament line-
age. Table 3 summarizes these studies as all ﬁndings were clustered
into 6 categories. Table 3 makes it evident that most research looks at
TNMD on a messenger level with the use of PCR to demonstrate that
the used cell types are or have differentiated into tendon-like cells.
Protein data on the other hand is shown very rarely. Based on our expe-
rience, it is the protein data that is most difﬁcult to gain, but it is an es-
sential proof of the true involvement of TNMD in the investigated
model. We and our Japanese collaborators have produced self-made
antibodies and examined their speciﬁcity using Tnmd knockdown
or knockout samples (Docheva et al., 2005; Shukunami et al., 2006;
Komiyama et al., 2013). It is therefore crucial for researchers to carefully
validate the antibody speciﬁcity.
Interestingly, several wound healingmodels, namely in skin, rotator
cuff and patella tendons, revealed differential Tnmd expression. In skin,
Tnmd expression signiﬁcantly downregulated between day 1 and 3 after
skin incision, while in the tendon defect studies Tnmd expression signif-
icantly upregulated in the period between 1–2 weeks in the patella and
between 4–12 weeks in the rotator cuff that was FGF-2 treated
(Kameyama et al., 2015; Omachi et al., 2015; Tokunaga et al., 2015).
This data strongly motivates further investigations on the exact roles
of Tnmd in tissue repair.
2.8. Tenomodulin correlations to various diseases
In recent years, research mostly conducted on a genomic level by
single nucleotide polymorphism (SNP), has presented very interesting
correlations between TNMD and a variety of diseases. Speciﬁcally,
TNMD was selected as a candidate gene for obesity, type 2 diabetes,
metabolic syndrome, Alzheimer's disease and age-related macular de-
generation, etc. The stated association studies are summarized in
Table 4, and the concrete TNMD SNPs are shown in Fig. 7.Associations with obesity, type 2 diabetes and metabolic syndrome
were investigated in two study populations; the Finnish diabetes pre-
vention study and the metabolic syndrome in men (Tolppanen et al.,
2007; Tolppanen et al., 2008a; Tolppanen et al., 2008b). In these studies
several gender-speciﬁc SNPs were identiﬁed; however it is still not
exactly known how these SNPs affect TNMD transcription, splicing or
protein amino acid sequence. Intriguingly most of the identiﬁed SNPs
are found in introns and not in exons or near exon–intron splice sites.
Only SNP rs2073162 is found on exon 3, suggesting that the key SNPs
might have a long-distance effect on transcriptional control. A follow
up study has revealed that TNMD expression is increased in obesity
and down-regulated during weight-reducing diet (Saiki et al., 2009). A
similar ﬁnding was also reported by Kolehmainen et al. (2008), the au-
thors found a strong downregulation of the TNMD gene along with
weight reduction. Moreover, the expression of TNMD was associated
with several characteristics of the metabolic syndrome, but the mecha-
nisms bywhich TNMDmaybe involved in insulin sensitivity remain elu-
sive. Other three studies have looked into correlations between TNMD
SNPs, or expression, to metabolic syndrome and reported certain links
to serum lipoproteins levels and inﬂammatory factors (Tolppanen
et al., 2008a; Tolppanen et al., 2008b; Gonzalez-Muniesa et al., 2013).
One circulated idea is that an increase in TNMD expression during
obesity might exert a protective mechanism aimed at limiting growth
of new blood vessels in periods of adipose tissue expansion. There are
still many open questions to these studies: for example, which cell
type expresses TNMD mRNA and how abundant is the protein; if and
how TNMD regulates the vascular formation and can it even directly af-
fect adipose cells; how Tnmdmight be involved in cholesterol metabo-
lism or can affect systemic immune mediators.
Tolppanen et al. (2011) suggested TNMD as an interesting candidate
gene for Alzheimer's disease since they detected associations between
TNMD SNPs and known risk factors for this disease. The sequence vari-
ation of TNMD was not connected with the prevalence of Alzheimer's
disease when the results were adjusted to the APOE genotype, but the
marker rs5966709 was linked with disease risk among women with
APOE Ɛ4-allele. These results suggest that the effect of APOE may be
modiﬁed by TNMD. Brandau et al. (2001) has shown by in situ hybridi-
zation a Tnmd messenger in multiple areas of the adult mouse brain,
however it is not clear if the protein is expressed, hence it would be
very interesting to follow up on the above studies and explain possible
functions of TNMD in the brain and brain diseases.
Age-related macular degeneration can be divided into atrophic and
exudative forms, the latter being more common and accounting for ap-
proximately 80% of age-related macular degeneration cases. Since dys-
regulated neovascularization is involved in the pathogenesis of age-
related macular degeneration, Tolppanen et al. (2009) also investigated
the associations of TNMD SNPs with this condition and found
rs1155974, rs2073163 and rs7890586 were correlating with higher
risk in women. This study further supported the theory of a disrupted
Table 3
The use of TNMD, Tnmd as a lineage marker.
Study type Experimental models TNMD expression found by Number of
articles
References
PCR ISH MA NB WB ICC IHC
Cell phenotypisation
(proliferation or
differentiation) with growth
factors/gene overexpression
In vitro using mouse, rat,
dog and human cells
21 2 2 9 7 26 Chen et al. (2015); Li et al. (2015); Liu et al.
(2015); Wada et al. (2015); Zhang et al., 2015;
Mohanty et al. (2014); Shimada et al. (2014);
Zhang et al., 2014; Fong et al. (2013); Gulati et al.
(2013); Qiu et al. (2013); Rothan et al. (2013); Rui
et al. (2013); Shen et al. (2013); Xia et al. (2013);
Alberton et al. (2012); Lovati et al. (2012); Sassoon
et al. (2012); Takimoto et al. (2012); Backman
et al. (2011); Lee et al. (2011); Schneider et al.
(2011); Haddad-Weber et al. (2010); Park et al.
(2010); Violini et al. (2009); Yeh et al. (2005)
Characterization of tendon
cells in culture
In vitro using mouse, rat,
rabbit and human cells
13 1 1 2 1 17 Kato et al. (2015); Zhang et al., 2015; Mienaltowski
et al. (2013); Al-Sadi et al., 2011; Busch et al.
(2012); Inoue et al. (2012); Lee et al. (2012) Leone
et al. (2012); Mazzocca et al. (2012); Tan et al.
(2012a); Tan et al. (2012b); Wagenhauser et al.
(2012); Hasegawa et al. (2010); Pauly et al. (2010);
Rui et al. (2010); Itaya et al. (2009); Yeh et al. (2008)
Mechanical stimulation on
cells and tendons
In vitro and in vivo with
mouse and rat cells and
tendons
3 3 Xu et al. (2015); Zhang and Wang (2013); Eliasson
et al. (2009)
Tissue engineering, 3D
combination of stem cells
with biomaterials and/or
growth factors
In vitro, ex vivo and in vivo
using mouse, rat, rabbit,
dog, pig, sheep, horse, cow
and human cells
24 3 2 3 26 Brown et al. (2015); Herchenhan et al. (2015);
Musson et al. (2015); Otabe et al. (2015); Pawelec
et al. (2015); Qin et al. (2015); Theiss et al. (2015);
Wagenhauser et al. (2015); Wang et al. (2015);
Barsby et al. (2014); Klatte-Schulz et al. (2014);
Mitani et al. (2014); Mizutani et al. (2014);
Moshaverinia et al. (2014); Subramony et al.
(2014); Tang et al. (2014); Younesi et al. (2014);
Erisken et al. (2013); Chen et al. (2012); Kishore
et al. (2012); Omae et al. (2012); Peach et al.
(2012); Tong et al. (2012); Zhu et al., 2010; Bashur
et al. (2009); Omae et al. (2009)
Developmental analyses In vivo using zebraﬁsh,
mouse, chicken and sheep
5 2 1 7 Murata et al. (2015); Russo et al. (2015); Chen and
Galloway (2014); Liu et al. (2012), Liu et al. (2010);
Lorda-Diez et al. (2009); Brandau et al. (2002)
Tendon healing and
expression analyses in
tissues
In vivo using mouse, rat
rabbit, horse and human
tissues
14 1 1 15 Kameyama et al. (2015); Omachi et al. (2015);
Rubio-Azpeitia et al. (2015);Tokunaga et al.
(2015); Kaux et al. (2014); Carvalho Ade et al.
(2013); Johansson et al. (2012); Kaux et al. (2012);
Mendias et al. (2012); Watts et al. (2012); Scott et al.
(2011); Watts et al. (2011); Jelinsky et al. (2010);
Minogue et al. (2010); Mendias et al. (2008)
Abbreviations: 3D, three dimensional; ICC, immunocytochemistry; IHC, immunohistochemistry; ISH, in situ hybridization; MA, microarray; NB, Northern blot; PCR, polymerase chain re-
action; WB, western blot.
12 S. Dex et al. / Gene 587 (2016) 1–17balance between stimulators and inhibitors of neovascularization in the
pathogenesis of exudative age-related macular degeneration. However,
functional studies are needed to reveal the exact mechanisms and in-
volvement of TNMD in these associations.
Due to the presence of TNMD in tendinous structures TNMDwas in
the spotlight also in heart-related studies. In fact, the anatomical organi-
zation of the CTCs, which connect the papillary muscle to the atrioven-
tricular valves, is very similar to tendons but of much smaller size. Their
rupture is awell-known cause ofmitral regurgitation and cardiac valvu-
lar syndromes. At the base of these failures is the abrogated avascularity
of the cordis (Kimura et al., 2008; Hakuno et al., 2011). The study by
Kimura et al. (2008) strongly conﬁrmed that the local absence of
TNMD leads to enhanced angiogenesis, VEGF-A and MMPs activation
following the rupture of the heart chordae tendineae. In the above
study TNMD knockdown experiments have suggested that TNMD can
directly inhibit endothelial cell migration, but the receptor ormolecular
agent through which Tnmd acts has not been found.
The associations with juvenile dermatomyositis were studied by
Chen et al. (2008) revealing that TNMDmRNA was upregulated dur-
ing the chronic inﬂammatory phase. The authors suggested that
TNMD might regulate contractility of vascular smooth muscle cellsand speculated that interventions that diminish the anti-angiogenic re-
modelling may be beneﬁcial for children with longer duration of un-
treated juvenile dermatomyositis. However, there is little information
describing how exactly TNMD is involved in vasculature loss and tissue
remodelling.
Last, a case report study of two female patients with intellectual dis-
ability and seizures related to female-restricted epilepsy with mental
retardation found a genomic deletion at PCDH19, spanning the TNMD
gene (Vincent et al., 2012). Despite being a case study, it would be
very interesting, after validation of TNMD protein expression in the
brain, to examine if Tnmd knockout animals exhibit a brain phenotype
and altered behaviour.
In summary, now that it is apparent that certain SNPs linked to
several health conditions are located in the TNMD locus and that chang-
es in the TNMD levels are associated with at least three different disease
it becomes almost obligatory in future research to provewhether or not
these associations have a critical role in the establishment of these dis-
eases and especially how the SNPs affect TNMD gene expression or pro-
tein production and function. One way to continue is to challenge the
Tnmd knockout strain by crossing it with mouse strains harbouring a
concrete disease phenotype. We believe that the uncovering of the
Table 4
Summary of studies correlating TNMDwith various diseases.
Diseases Study model TNMD
analysis
Main conclusions References
Obesity Longitudinal study, 166 men and 341 women with
overweight and impaired glucose tolerance
TNMD
SNPs
rs5966709 and rs4828037 were associated with adiposity
in women; rs11798018 was related with adiposity in men.
Tolppanen et al. (2007)
Longitudinal study, 68 obese cases, subcutaneous
adipose tissue, omental adipose tissue
TNMD
mRNA
TNMD was highly expressed in adipose tissue and
increased in obesity and was down-regulated during
diet-induced weight loss in men and women.
Saiki et al. (2009)
Longitudinal study, 28 weight reduction cases and
18 controls, fat tissue
TNMD
mRNA
Strong downregulation of TNMD expression after
long-term weight reduction in men and women.
Kolehmainen et al. (2008)
Type 2 diabetes Longitudinal study, 166 men and 341 women with
overweight and impaired glucose tolerance
TNMD
SNPs
rs2073163 and rs1155974 were linked with 2-h plasma
glucose in men; rs2073163, rs1155974, and rs2073162
were associated with type 2 diabetes in men; only
rs2073162 associated with 2-h plasma glucose in women.
Tolppanen et al. (2007)
Metabolic syndrome Cross-sectional study, random sample of 5298 men TNMD
SNPs
rs2073162 was related with serum lipoproteins in a
BMI-dependent manner in men; no women were involved
in the research.
Tolppanen et al. (2008a)
Longitudinal study, 9 lean and 9 obese male high fat
cases, subcutaneous abdominal adipose tissue
TNMD
mRNA
Expression of TNMD was linked with some relevant
metabolic syndrome features in men; no women were
involved in the research.
Gonzalez-Muniesa et al.
(2013)
Cross-sectional study, 166 men and 341 women
with overweight and impaired glucose tolerance
TNMD
SNPs
rs2073163, rs1155974, and rs2073162 were connected
with acute phase reactants in men; rs5966709 and
rs4828037 were associated with inﬂammatory factors in
men and women; rs2073163, rs4828038, and rs1155974
were related with inﬂammatory factors in women.
Tolppanen et al. (2008b)
Alzheimer's disease Cross-sectional study, 526 Alzheimer's disease
cases and 672 controls
TNMD
SNPs
rs5966709 was connected with risk of Alzheimer's disease
among women with AOPE Ɛ4-allele; none of the SNPs
associated with Alzheimer's disease in men.
Tolppanen et al. (2011)
Age-related macular
degeneration
Cross-sectional study, 307 age-related macular
degeneration cases and 168 controls
TNMD
SNPs
rs1155974 and rs2073163 were associated with a risk of
age-related macular degeneration in women; none of the
SNPs associated with prevalence of age-related macular
degeneration among men.
Tolppanen et al. (2009)
Rupture of the chordae
tendineae cordis
Cross-sectional study, 12 normal and 16 ruptured
chordae tendineae cordis (CTC), specimens
obtained from autopsy or surgery,
immunohisto-chemical analysis
TNMD
protein
TNMD was locally absent in the rupture area, where
abnormal vessel formation, strong expression of vascular
endothelial growth factor-A and matrix metalloproteinases,
and inﬁltration of inﬂammatory cells were observed, but
not in the normal or non-ruptured CTC.
Kimura et al. (2008)
Juvenile
dermatomyositis
Cross-sectional study, 31 girls with Juvenile
dermatomyositis and 4 healthy controls, muscle
biopsies
TNMD
mRNA
TNMD was up-regulated during the chronic inﬂammatory
state of the disease, and down-regulated when disease
duration was short in girls, no boys were involved in the
research.
Chen et al. (2008)
Intellectual disability
and seizures
Case report, two female patients, deletions
spanning PCDH19
TNMD
gene
Genomic deletions spanning the TNMD gene in
female-restricted epilepsy with mental retardation.
Vincent et al. (2012)
Abbreviations: APOE, apolipoprotein E; CTC, chordae tendineae cordis; mRNA, messenger ribonucleic acid; PCDH19, Protocadherin 19; rs, reference SNP; SNP, single nucleotide polymor-
phism; TNMD, tenomodulin.
Fig. 7. Single nucleotide polymorphism (SNPs) andother putativemutations in the TNMD gene locus correlatingwith various diseases. Orange boxes represent exons,while the connecting
black lines are introns. Abbreviations: rs, reference SNP; SNPs, small nucleotide polymorphisms; UTR, untranslated region.
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Fig. 8. Schematic summary of TNMD known functions. Abbreviations: mRNA, messenger ribonucleic acid; Tnmd, tenomodulin; VEGF, vascular endothelial growth factor.
14 S. Dex et al. / Gene 587 (2016) 1–17exact TNMD functionswill be essential for improving our understanding
of the mentioned clinical conditions, which subsequently will permit
the development of appropriate counterstrategies.
3. Conclusion and future perspectives
Since its discovery in 2001, TNMD has gained signiﬁcantly more at-
tention as demonstrated in the increasing number of articles in the
last 15 years. The alternative names have been condensed to the single
name tenomodulin with its corresponding abbreviation as TNMD. It is a
gene bearing high and only homology to Chm1, but still exhibits impor-
tant differences, such as the absence of a furin cleavage signal, different
glycosylation sites and expression pattern. Although the predominant
expression of TNMD is found in tendons and ligaments, it is also
shown to be expressed in other tissues such as parts of the eyes, cordae
tendineae cordis, muscle sheaths, brain, fat and skin. The presence of
isoforms needs to be carefully veriﬁed in different species. Another
very important future goal should be the better understanding of the
TNMD protein domain structure. The TNMD signalling pathway is still
very elusive as up to date only few upstream factors, such as Scx and
Mkx, have been identiﬁed. With regards to downstream effectors,
there is a complete lack of knowledge on the direct protein binding
partners of TNMD. The full clariﬁcation of TNMD signalling must be-
come central in follow up research, because by only elucidating TNMD
modes of action we would be able to speciﬁcally manipulate its effect
in tendons and other tissues. We have summarized the current discov-
ered functions of TNMD in Fig. 8. Firstly, TNMD has been strongly justi-
ﬁed as the best tendon and ligament marker in more than 90 different
studies. Next, a combination of in vivo and in vitro investigations has re-
vealed its positive role on tendon/ligament cell and tissue functions as
well as is negative effect on vessels in speciﬁc regions of the heart and
in tumour models. Last, we are just starting to comprehend the poten-
tial involvement of TNMD in various diseases such as obesity and meta-
bolic syndrome, where TNMD expression is positively correlated to an
advanced disease state. However, since most of the disease-associated
studies are based on identiﬁcation of SNPs in TNMD gene locus it is
very important to ﬁnd out how exactly these mutations translate into
these diseases. In sum, we believe that this review not only summarizes
the current state of affairs of our knowledge of TNMD gene, protein,
expression and functions, but also will excite international researchers
to further study this mysterious tenogenic modulating insider factor interms of complete deciphering of its signalling pathway, contribution
to certain pathologies as well as possible development of therapeutic
strategies.
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